Denali, ALS
Denali Therapeutics Says ALS Trial Didn't Meet Endpoints
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks. The biotechnology company said Monday that DNL343 didn't meet the primary endpoint of slowing disease progression as compared with a placebo.
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Holland America Line has announced a $70 million capital investment to expand guest capacity while elevating the line's ...
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...
HAL is planning a $70 million expansion over the next three years, including the construction of a new guestroom building.
Holland America Line announced a $70M capital investment that will expand guest capacity while elevating the line’s Denali property experience ...
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Hosted on MSN23h
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback